Abstract Number: 2633 • 2018 ACR/ARHP Annual Meeting
Disease Activity, Organ Damage and Patient-Reported Outcome Measures in Swedish Patients with Recent-Onset SLE
Background/Purpose: Patient (pt)-reported outcome measures (PROMs) are important to inform shared decision-making between pts with SLE and physicians.1 Established measures of disease activity and organ…Abstract Number: 2634 • 2018 ACR/ARHP Annual Meeting
The Risk of Hydroxychloroquine Retinopathy in an SLE Cohort: Screening and Prevention in Clinical Practice
Background/Purpose: Hydroxychloroquine (HCQ) is a commonly used medication for SLE because of its highly favorable risk-benefit ratio. Drug-induced retinopathy is one of very few serious…Abstract Number: 2635 • 2018 ACR/ARHP Annual Meeting
Combined Panel of Nine Tests Has the Greatest Sensitivity but the Lowest Specificity to Detect Antiphospholipid Antibody Syndrome in Patients with Systemic Lupus Erythematosus
Background/Purpose: Antiphospholipid antibody syndrome (APS) is an autoimmune hypercoagulable state caused by antiphospholipid antibodies (aPL) which represent a diagnostic criterion and underlie significant comorbidities in…Abstract Number: 2636 • 2018 ACR/ARHP Annual Meeting
Investigating Lupus Nephritis Patient Outcomes Receiving Belatacept Post Renal Transplant Using the UNOS Database
Background/Purpose: Twenty to sixty percent of patients with systemic lupus erythematous (SLE) can progress to lupus nephritis (LN) and those that do can develop end…Abstract Number: 2637 • 2018 ACR/ARHP Annual Meeting
Hydroxychloroquine Improves Disease Activity and Allows Reduction of Corticosteroid Dose Regardless of Background Treatment in Japanese Patients with Systemic Lupus Erythematosus
Background/Purpose: Hydroxychloroquine (HCQ) was not approved in Japan until 2015 and its therapeutic potential remains poorly understood in the population. In this study, we evaluated…Abstract Number: 2638 • 2018 ACR/ARHP Annual Meeting
Tacrolimus Use in Hispanic Patients with Refractory Lupus Nephritis
Background/Purpose: Lupus nephritis is one of the most common and severe manifestations of patients with SLE. Studies assessing the use of Tacrolimus (TAC) in lupus…Abstract Number: 2639 • 2018 ACR/ARHP Annual Meeting
Bone Mineral Density Is Not Associated with Osteoporotic Fractures in Premenopausal Women and Men < 50 Years Old with Systemic Lupus Erythematosus
Background/Purpose: Osteoporosis is common in patients with systemic lupus erythematosus (SLE). Guidelines for the treatment and prevention of glucocorticoid induced osteoporosis (GIOP) are detailed for…Abstract Number: 2640 • 2018 ACR/ARHP Annual Meeting
Hematologic Activity in Systemic Lupus Erythematosus: Is Splenectomy Our Best Choice?
Background/Purpose: Hematologic manifestations are found in up to 30% of SLE patients. Although splenectomy is considered an acceptable therapeutic option for both refractory thrombocytopenia and…Abstract Number: 2641 • 2018 ACR/ARHP Annual Meeting
Hydroxychloroquine Could Modulate S100 Proteins Expression, Which Reflect the Activity of Lupus Nephritis or Skin Lesion, in Systemic Lupus Erythematosus Patients with Low Disease Activity
Background/Purpose: To find the effect of HCQ treatment on expression of S100 proteins which were reported to reflect the activity of SLE including lupus nephritis…Abstract Number: 2642 • 2018 ACR/ARHP Annual Meeting
Atacicept Dose Rationale for a Phase 3 Study in Patients with High Disease Activity and Auto-Antibody Positive SLE
Background/Purpose: Atacicept targets the B-cell-stimulators BLyS and APRIL, and is in development for the treatment of patients (pts) with SLE. Here, we integrated non-clinical and…Abstract Number: 2643 • 2018 ACR/ARHP Annual Meeting
Sledai-2K Responder Index-50 Is Effective in Demonstrating Partial Response in a Phase 2, Randomized Placebo-Controlled Study of Ustekinumab in Patients with Active Systemic Lupus Erythematosus
Background/Purpose: Ustekinumab (UST), a monoclonal antibody that targets the shared p40 subunit of the cytokines IL-12 & IL-23, is being investigated in patients (pts) w/…Abstract Number: 2644 • 2018 ACR/ARHP Annual Meeting
Identifying Response for the Systemic Lupus Erythematosus Disease Activity Glucocorticoid Index (SLEDAI-2KG)
Background/Purpose: Systemic Lupus Erythematosus Disease Activity Index-2000 (SLEDAI-2K) Glucocorticoid Index (SLEDAI-2KG) is a valid index able to measure disease activity while accounting for glucocorticoid (GC)…Abstract Number: 2645 • 2018 ACR/ARHP Annual Meeting
The Impact of Metformin on Disease Activity in Systemic Lupus Erythematosus
Background/Purpose: Metformin is a mainstay of therapy for type 2 diabetes mellitus. Newer evidence suggests that metformin may reduce lupus flares. An entity called neutrophil…Abstract Number: 2646 • 2018 ACR/ARHP Annual Meeting
Disparities in Antimalarial Prescribing for Systemic Lupus Erythematous Nephritis Using a Real-World, Electronic Health Record
Background/Purpose: Antimalarials (AMs) improve survival in patients with systemic lupus erythematosus (SLE). Current guidelines suggest AMs for all SLE nephritis patients. Studies using patient-reported data…Abstract Number: 2647 • 2018 ACR/ARHP Annual Meeting
Comparison of Low-Dose Intravenous Cyclophosphamide with Oral Mycophenolate Mofetil in the Treatment of Lupus Nephritis: Long Term Follow-up Data
Background/Purpose: We present the long-term follow-up of patients with lupus nephritis who completed the randomized controlled trial on comparison of low-dose intravenous cyclophosphamide (IV CYC)…